X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
evolocumab (340) 340
index medicus (241) 241
humans (179) 179
alirocumab (162) 162
hypercholesterolemia (149) 149
cardiac & cardiovascular systems (148) 148
cholesterol (134) 134
statins (131) 131
evolocumab amg 145 (121) 121
heterozygous familial hypercholesterolemia (118) 118
pcsk9 (117) 117
efficacy (113) 113
safety (110) 110
monoclonal-antibody (109) 109
familial hypercholesterolemia (104) 104
double-blind (101) 101
pharmacology & pharmacy (100) 100
density-lipoprotein cholesterol (99) 99
cardiovascular disease (95) 95
subtilisin/kexin type 9 (89) 89
lipids (86) 86
low density lipoproteins (86) 86
placebo-controlled trial (80) 80
proprotein convertase 9 - antagonists & inhibitors (80) 80
cardiovascular diseases (75) 75
antibodies, monoclonal - therapeutic use (73) 73
monoclonal antibodies (73) 73
reducing lipids (73) 73
anticholesteremic agents - therapeutic use (72) 72
hypercholesterolemia - drug therapy (71) 71
cholesterol, ldl - blood (70) 70
pcsk9 inhibitors (69) 69
coronary-heart-disease (66) 66
ldl cholesterol (66) 66
risk factors (64) 64
statin therapy (64) 64
atherosclerosis (62) 62
peripheral vascular disease (62) 62
lipoproteins (58) 58
risk (57) 57
ldl-c (56) 56
low density lipoprotein (56) 56
treatment outcome (54) 54
male (50) 50
female (49) 49
proprotein convertase 9 (47) 47
dyslipidemia (46) 46
ezetimibe (46) 46
endocrinology & metabolism (45) 45
middle aged (45) 45
clinical trials (44) 44
ldl-cholesterol (44) 44
cardiovascular diseases - prevention & control (42) 42
cardiology (41) 41
care and treatment (41) 41
cardiovascular (40) 40
medicine & public health (40) 40
proprotein convertase subtilisin/kexin type 9 (40) 40
medicine, general & internal (39) 39
therapy (39) 39
diabetes (38) 38
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (38) 38
pcsk9 inhibition (38) 38
proprotein convertase 9 - metabolism (38) 38
antibodies, monoclonal - adverse effects (36) 36
drug therapy (36) 36
low-density lipoprotein cholesterol (36) 36
pcsk9 inhibitor evolocumab (36) 36
cardiovascular risk (35) 35
cardiovascular-disease (34) 34
aged (33) 33
kexin (33) 33
subtilisin (33) 33
amg 145 (32) 32
anticholesteremic agents - adverse effects (32) 32
cardiovascular events (32) 32
hypercholesterolemia - blood (32) 32
patients (32) 32
prevention (32) 32
analysis (31) 31
animals (31) 31
cardiovascular agents (31) 31
proprotein convertases - antagonists & inhibitors (31) 31
abridged index medicus (30) 30
disease (30) 30
cost-effectiveness (29) 29
ldl (29) 29
medical research (29) 29
low-density-lipoprotein (28) 28
research (28) 28
cholesterol, ldl (27) 27
hyperlipidemia (27) 27
mortality (27) 27
randomized controlled-trial (27) 27
lipoprotein (26) 26
metaanalysis (26) 26
randomized-trial (26) 26
biomarkers - blood (25) 25
diabetes mellitus (25) 25
dyslipidemias - drug therapy (25) 25
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (439) 439
Spanish (15) 15
German (11) 11
Czech (4) 4
French (2) 2
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
Portuguese (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Heart Journal, ISSN 0195-668X, 04/2018, Volume 39, Issue 14, pp. 1169 - 1171
Journal Article
European Heart Journal Supplements, ISSN 1520-765X, 03/2019, Volume 21, Issue Supplement_B, pp. B48 - B49
Journal Article
European Heart Journal, ISSN 0195-668X, 2016, Volume 37, Issue 48, pp. 3596 - 3599
Journal Article
Russian Journal of Cardiology, ISSN 1560-4071, 2017, Volume 145, Issue 5, pp. 85 - 90
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2018, Volume 39, Issue 5, pp. 382 - 384
Journal Article
Cardiology Clinics, ISSN 0733-8651, 05/2018, Volume 36, Issue 2, pp. 241 - 256
Journal Article
Revista Espanola de Cardiologia, ISSN 0300-8932, 12/2018, Volume 71, Issue 12, pp. 1010 - 1017
Introduction and objectives: PCSK9 inhibitors (PCSK9i) are safe and effective lipid-lowering drugs. Their main limitation is their high cost. The aim of this... 
PCSK9 inhibitors | Alirocumab/evolocumab | Therapeutic indication | Low-density lipoprotein cholesterol
Journal Article
European Heart Journal, ISSN 0195-668X, 07/2018, Volume 39, Issue 27, pp. 2577 - 2585
Abstract Aims Lipoprotein(a) [Lp(a)], a low-density lipoprotein (LDL) particle covalently bound to apolipoprotein(a) [apo(a)], is a potentially potent... 
FAMILIAL HYPERCHOLESTEROLEMIA | CARDIAC & CARDIOVASCULAR SYSTEMS | PLASMA LIPOPROTEIN(A) | HUMANS | PCSK9 | Lp(a) | APOLIPOPROTEIN(A) | DIABETES-MELLITUS | SERIES LIPOPROTEIN | apo(a) | METABOLISM | Evolocumab | MONOCLONAL-ANTIBODY INHIBITION | PCSK9 INHIBITION | Atorvastatin
Journal Article
Expert Review of Cardiovascular Therapy, ISSN 1477-9072, 05/2015, Volume 13, Issue 5, pp. 477 - 488
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2019, Volume 105, Issue 2, pp. 496 - 504
In randomized clinical trials ( RCT s) proprotein convertase subtilisin/kexin 9 ( PCSK 9) inhibitors showed a favorable safety profile, however, “real‐world”... 
ANTIBODIES | DRUG-REACTIONS | TRIALS | ALIROCUMAB | METAANALYSIS | EFFICACY | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HYPERCHOLESTEROLEMIA | EVOLOCUMAB | Research
Journal Article
Journal of Clinical Lipidology, ISSN 1933-2874, 05/2019, Volume 13, Issue 3, pp. 411 - 414
We present a 37-year-old man diagnosed with familial dysbetalipoproteinemia who presented with the severe hyperlipidemic phenotype. None of the usual metabolic... 
Dysbetalipoproteinemia | Hypercholesterolemia | Sitosterolemia | Sterols | Evolocumab | Ezetimibe | PHARMACOLOGY & PHARMACY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.